Close this search box.
Close this search box.
Close this search box.

G2MC 3rd International Conference

April 27 - 29, 2017

Athens, Greece


The G2MC 3rd International Conference has concluded. A huge thanks to our sponsors, organizing partners, planning committee, speakers, and attendees for making this a successful event!

About the Event

The 3rd Global Genomic Medicine Collaborative (G2MC) conference was held in Athens on April 27-29, 2017, with over 120 delegates from nearly 50 countries. The meeting included the following sessions:

  • Large-Scale National Sequencing Programs: Impact on Clinical Medicine
  • Progress in Diagnosing Rare Diseases – International Opportunities
  • National Genomic Medicine Programs: Implementation
  • Data Science
  • Policy and Workforce Generation
  • Pharmacogenomics in the Clinic: International Progress
  • Implementation of Genomic Medicine by the Private Sector
  • covered topics including national sequencing programs, rare disease diagnosis, national genomic medicine programs, data science, policy and workforce, pharmacogenomics, and the private sector.

Key Takeaways

Key takeaways from the meeting include the need for increased collaboration and data sharing, the importance of developing standardized guidelines and tools for clinical variant interpretation, and the challenges of implementing genomic medicine in different countries and healthcare systems. The meeting also highlighted the need for increased public awareness and education about genomics, as well as the importance of involving patients and the public in the development of genomic medicine policies and programs. Additionally, there were discussions on the use of pharmacogenomics information cards, the development of a common method for collecting family health history, and the need for more evidence to support the implementation of genomic medicine in mainstream use. The meeting concluded with breakout sessions on various topics, including national implementation programs, policy, pharmacogenomics, education, IT/bioinformatics, and evidence, with the goal of developing action plans and identifying next steps for each area.